Maya Margalit

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

Rohit Loomba, Arun J. Sanyal, Kris V. Kowdley et al. · New England Journal of Medicine · 2023 · 442 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +9

Combination Immunomodulator and Antibiotic Treatment in Patients With Inflammatory Bowel Disease and Clostridium difficile Infection

Shomron Ben‐Horin, Maya Margalit, Peter Bossuyt et al. · Clinical Gastroenterology and Hepatology · 2009 · 140 citations

Veterinary Medicine, Immunology, Pharmacotherapy +17

Adoptive transfer of regulatory NKT lymphocytes ameliorates non‐alcoholic steatohepatitis and glucose intolerance in ob/ob mice and is associated with intrahepatic CD8 trapping

Eran Elinav, Orit Pappo, M. Sklair-Levy et al. · The Journal of Pathology · 2006 · 112 citations

Life Sciences, Immunology, Pathology +16

Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study

Rohit Loomba, Eric Lawitz, Juan P. Frías et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 99 citations

Pharmacy, Pharmacokinetics, Pharmacology +8

β-Glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders

Ehud Zigmond, Sarah Preston, Orit Pappo et al. · Gut · 2006 · 89 citations · Full text

Life Sciences, Immunology, Pharmacology +14